Lunit KRX:328130KOSDAQ

루닛 · Korean news coverage and regulatory filings, organized.

Articles, 24h2
Articles, 7 days49
DART filings, 7 days0
Articles tracked222since Sep 11

In Q2 2026, Lunit reported revenue of ₩21.8bn, up 22.0% year on year, and an operating loss of ₩15.4bn. Lunit (루닛) appeared in 49 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 33 articles. The most common catalyst was tech & capacity (8). It was most often mentioned alongside Vuno, 글로벌테크놀로지 and Seers.

Filing signals 4 quarters of losses Screener

Lunit quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩21.8bn+22.0%−₩15.4bn
margin −70.5%
−₩23.6bn
Q1 2026₩24.0bn+24.7%−₩13.6bn
margin −56.8%
−₩17.8bn
Q4 2025 derived₩26.5bn+32.1%−₩19.6bn
margin −74.2%
−₩32.4bn
Q3 2025₩19.6bn+16.7%−₩21.6bn
margin −110.1%
₩18.1bn
Q2 2025₩17.9bn+46.2%−₩21.1bn
margin −118.1%
−₩35.0bn
Q1 2025₩19.2bn+273.6%−₩20.7bn
margin −107.6%
₩2.0bn
Q4 2024 derived₩20.0bn+271.3%−₩18.5bn
margin −92.3%
−₩73.4bn
Q3 2024₩16.8bn+413.3%−₩16.4bn
margin −98.0%
−₩11.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Lunit top stories 2 weeks, by number of outlets

  1. 1
    루닛, ESMO 2026서 AZ·다이이찌산쿄 참여 ‘AI 프로젝트’ 연구 결과 공개
    4 outlets · 4 articlesFirst report Oct 20 08:13 더바이오
  2. 2
    루닛, 美 서밋과 항암 신약 개발 협력에 급등
    2 outlets · 2 articlesFirst report Oct 26 09:18 한국경제Partnership
  3. 3
    루닛, "유방암 '초저발현 HER2' AI 분석 결과 ESMO서 공개"
    2 outlets · 2 articlesFirst report Oct 20 08:15 머니투데이
  4. 4
  5. 5
    루닛, 장 중 상한가…美 항암제 개발 협력·재평가 기대감 영향
    2 outlets · 2 articlesFirst report Oct 26 09:29 머니투데이Partnership
  6. 6
    루닛, '美 바이오기업과 협업'에 장 초반 강세
    2 outlets · 2 articlesFirst report Oct 26 09:37 연합뉴스경제

Latest Lunit news Korean headlines